These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 7588084)

  • 1. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.
    Rains CP; Noble S; Faulds D
    Drugs; 1995 Jul; 50(1):137-56. PubMed ID: 7588084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying antirheumatic drugs. Potential effects in older patients.
    Gardner G; Furst DE
    Drugs Aging; 1995 Dec; 7(6):420-37. PubMed ID: 8601050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
    Capell HA; Madhok R; Porter DR; Munro RA; McInnes IB; Hunter JA; Steven M; Zoma A; Morrison E; Sambrook M; Wui Poon F; Hampson R; McDonald F; Tierney A; Henderson N; Ford I
    Ann Rheum Dis; 2007 Feb; 66(2):235-41. PubMed ID: 16926184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs.
    Dale J; Alcorn N; Capell H; Madhok R
    Nat Clin Pract Rheumatol; 2007 Aug; 3(8):450-8; quiz, following 478. PubMed ID: 17664952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfasalazine: a review of its use in the management of rheumatoid arthritis.
    Plosker GL; Croom KF
    Drugs; 2005; 65(13):1825-49. PubMed ID: 16114981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of triple association methotrexate, sulfasalazine and hydroxychloroquine in early treatment of rheumatoid arthritis with insufficient response to methotrexate: Meta-analysis of randomized controlled trials.
    Mazouyès A; Clay M; Bernard AC; Gaudin P; Baillet A
    Joint Bone Spine; 2017 Oct; 84(5):563-570. PubMed ID: 27989589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
    Calgüneri M; Pay S; Calişkaner Z; Apraş S; Kiraz S; Ertenli I; Cobankara V
    Clin Exp Rheumatol; 1999; 17(6):699-704. PubMed ID: 10609068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine.
    Wojciechowski J; Wiese MD; Proudman SM; Foster DJ; Upton RN
    Br J Clin Pharmacol; 2015 May; 79(5):777-88. PubMed ID: 25394211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive triple DMARD combination therapy of a low dose of sulfhydryl compounds, sulfasalazine and methotrexate in the treatment of rheumatoid arthritis: a clinical trial.
    Nishiya K; Hisakawa N; Tahara K; Matsumori A; Ito H; Hashimoto K; Nakatani K; Takatori K
    Acta Med Okayama; 1999 Dec; 53(6):275-9. PubMed ID: 10631383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
    Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brief Report: Intensification to Triple Therapy After Treatment With Nonbiologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States From 2009 to 2014.
    Sparks JA; Krumme AA; Shrank WH; Matlin OS; Brill G; Pezalla EJ; Choudhry NK; Solomon DH
    Arthritis Rheumatol; 2016 Jul; 68(7):1588-95. PubMed ID: 26866506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Breedveld FC; Dijkmans BA;
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.
    Möttönen T; Hannonen P; Korpela M; Nissilä M; Kautiainen H; Ilonen J; Laasonen L; Kaipiainen-Seppänen O; Franzen P; Helve T; Koski J; Gripenberg-Gahmberg M; Myllykangas-Luosujärvi R; Leirisalo-Repo M;
    Arthritis Rheum; 2002 Apr; 46(4):894-8. PubMed ID: 11953964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
    Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
    Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
    Wabe N; Wojciechowski J; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Proudman S; Wiese MD
    Int J Rheum Dis; 2017 Oct; 20(10):1447-1456. PubMed ID: 28952204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and treatment options for rheumatoid arthritis during pregnancy.
    Gerosa M; Schioppo T; Meroni PL
    Expert Opin Pharmacother; 2016 Aug; 17(11):1539-47. PubMed ID: 27283340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.